

Executive Corridor
 Darlington Memorial Hospital
 Hollyhurst Road
 Darlington
 DL3 6HX
 Switchboard Tel: 01325 38 0100
 Foundation Trust Office: 01325 74 3625
 Corporate Records Office: 01325 74 3700

Request for Information Reference: 08.20.01

Email: cdda-tr.cddftfoi@nhs.net

Email only

1 September 2020

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 3 August 2020 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to atopic dermatitis treatments and I am providing the following information in response to your specific questions:

Number of Patients Treated

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast	113	196
Adalimumab	562	810
Dupilumab	0	72
Etanercept	324	512
Infliximab	175	153
Secukinumab	107	116
Ustekinumab	199	157

Please note that of the drugs in the table above, the Trust uses only Dupilumab as a treatment for atopic dermatitis.

2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
25	57

Please note that the information above is for inpatients only. This is based on a search for the clinical code for atopic dermatitis in any diagnosis position on inpatient records. Outpatient appointments are not coded and as such the Trust is unable to provide information. In order to provide this information the medical records of every patient who had attended a clinic appointment would need to be reviewed to understand if they had been diagnosed with atopic dermatitis and received treatment. Therefore the Trust is refusing this section of your request for information pursuant to section 12 of the Act on the grounds that we estimate that the cost of complying with the request would exceed the appropriate limit. The appropriate limit at the present time is £450.00 which equates to eighteen and quarter hours of work by a member of staff at the rate of £25 per hour.

3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast	0	0
Adalimumab	0	0
Dupilumab	0	72
Etanercept	0	0
Infliximab	0	0
Secukinumab	0	0
Ustekinumab	0	0

Please note that of the drugs in the table above, the Trust uses only Dupilumab as a treatment for atopic dermatitis.

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast	X92.1
Adalimumab	X92.1
Dupilumab	X92.1

Etanercept	X92.1
Infliximab	X92.1
Secukinumab	X89.1
Ustekinumab	X38.4

Please note that the codes provided above are no longer used by the Trust as of April 2020.

5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020
0	72

6. How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast	0	0
Adalimumab	0	0
Dupilumab	0	72
Etanercept	0	0
Infliximab	0	0
Secukinumab	0	0
Ustekinumab	0	0

Please note that of the drugs in the table above, the Trust uses only Dupilumab as a treatment for atopic dermatitis.

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. I am sorry that I have not been able to provide all of the information you requested, however I hope that my explanation as to why this is not possible has been satisfactory. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane,

Wilmslow, Cheshire, SK9 5AF. More information is available on their website;
www.ico.gov.uk.

Yours sincerely

Joanna Tyrrell
Freedom of Information Officer